Why are online pharmacies the obvious candidates?
The regulatory framework and the inspection findings are addressed elsewhere in this library, in the rules guide and the thematic review analysis. This article assumes that material. It addresses the question those pieces deliberately leave open: should an online pharmacy do it?
Three characteristics make distance-selling pharmacies the natural adopters. They hold volume concentrated in narrow product ranges. A business built around weight management, hair loss or contraception dispenses a small number of lines many thousands of times — precisely the profile automation rewards. They have no counter, so the physical dispensary serves no purpose beyond throughput. It can be optimised without regard to patient experience within the building. And they are already remote from the patient. The psychological objection a community pharmacist feels about a prescription assembled elsewhere does not arise in the same way, because the patient was never going to watch it being dispensed.
Add the operational reality. Scaling a dispensary is capital-intensive, slow and constrained by premises; scaling a hub relationship is a contract negotiation. The attraction is obvious. The rest of this article is about what the attraction obscures.
What does hub and spoke actually save?
Honestly assessed, less than the pitch suggests and more than the sceptics allow. The difference is determined almost entirely by scale.
The genuine savings sit in three places. Labour per item: automated assembly at volume substantially outperforms manual dispensing. Premises: dispensary space is expensive, and a hub converts fixed cost into variable. And capital avoided: the automation that produces the labour saving is bought by someone else.
Set against those are costs business cases routinely omit. The governance overhead increases rather than decreasing. The arrangement requires written agreements, oversight arrangements, audit of the hub's performance and the additional records the regulator expects — none of which existed when dispensing happened in one room under one pharmacist. There is margin transferred to the hub: the hub is a business earning from the arrangement, and the saving is what remains after it has taken its share. There is a transition cost: integration, process redesign and the period during which both models run. And there is the coordination cost of a supply chain with an extra party in it, which surfaces on the days something goes wrong rather than in the model.
The consequence is a threshold effect. Below a certain volume, the fixed governance and integration costs exceed the per-item saving. The arrangement makes a business more complicated without making it cheaper. Above it, the savings compound. Where that threshold sits varies by product mix and by the terms obtained. Any operator who has not calculated it on their own numbers is making the decision on atmosphere.
Does outsourcing dispensing commoditise your business?
Consider what a typical online pharmacy actually does itself once the arrangement is in place. Payments are handled by an acquirer. Delivery is handled by a carrier. Prescribing is often handled by contracted prescribers. The platform is built by an agency. And now dispensing is handled by a hub. What remains inside the business is a brand, a website and a regulatory licence. The operational capability that distinguished it from a competitor has been contracted out to suppliers that competitor can also engage. The endpoint is a market in which several operators — same hub, same carrier, comparable prescribing capacity — sell the same medicines to the same patients, and compete on the only dimension left: price. This is a familiar destination, not a hypothetical one; the analysis of the oral GLP-1 launch described precisely that dynamic arriving in the largest private category. So the decision is not merely operational. A business that differentiates through clinical service, follow-up and trust can outsource assembly without losing what it competes on. A business whose proposition was speed and convenience has just outsourced its proposition.
What happens if your hub fails?
A traditional pharmacy that loses hub access has a dispensary, stock and staff. It reverts to dispensing in-house while the difficulty is resolved. The arrangement degrades rather than stopping.
An online pharmacy that has closed its own dispensing capability has none of those things. There is no counter, no meaningful local stock, no automation and often no staff who have dispensed at volume for a year. When the hub hits a system failure, a regulatory intervention, a stock crisis or an insolvency, the business does not degrade. It stops — for every patient simultaneously, in a model whose entire promise was reliable delivery to the door.
The mitigations are unglamorous and should be contractual rather than aspirational. A service level with meaningful consequences rather than best endeavours. Continuity obligations specifying what happens during hub downtime and who bears the cost. A retained minimum capability — a smaller in-house dispensing function or a documented second hub arrangement — accepting that redundancy costs money and is worth what it costs. And notice periods long enough to rebuild. A hub entitled to terminate at ninety days holds a business that cannot rebuild in ninety days.
Concentration risk is the difference between an operational decision and a strategic one. It is the reason this article treats the subject as strategy rather than logistics.
Who owns the hub, and what do they learn about you?
A hub dispensing a pharmacy's prescriptions necessarily observes a great deal about that pharmacy. It sees volumes by line, growth rates, seasonality, product mix, average order values, the pace at which a new service scales, and the point at which a competitor's promotion moves demand. That is a clear commercial picture, assembled continuously. It is generated as a by-product of the service, not through anything improper.
Whether that matters depends on who owns the hub. Where the owner is an independent operator with no retail interest, the information is commercially sensitive but not competitively dangerous. Where the owner also operates a pharmacy, a group, or a platform in the same categories, the position is different. Establish it before signing, not after noticing.
Three protections are worth negotiating. Confidentiality extending to derived and aggregated data, not merely patient information — aggregation is exactly how the picture becomes useful. Restrictions on internal use for competing purposes, expressed in terms that mean something. And a defined position on what happens at termination, covering what is deleted and what may be retained.
This is not an argument against hub arrangements. It is an argument for reading the counterparty as carefully as the contract. This library applies the same discipline to payment partners and to web developers, for the same reason.
Who does the patient blame?
The pharmacy, always. This is where the regulatory position and the commercial one converge.
A patient whose parcel is late, whose item is wrong, or whose supply is interrupted does not distinguish between the pharmacy that took the order and the hub that assembled it. Nor should they. The pharmacy supplied the medicine, holds the professional relationship and appears on the label. The regulator takes the same view of accountability, as the rules guide sets out.
Commercially, a pharmacy outsourcing dispensing has outsourced its control over the experience while keeping full ownership of the consequences. It must therefore invest in the parts it still controls. That means visibility, so staff answering a query can see the actual status rather than promising to chase the hub. It means authority to resolve, so the pharmacy can put things right without waiting for a supplier's process. And it means hub performance treated as pharmacy performance in the weekly measures, because the patient experiences one business.
The reviews this produces are the pharmacy's reviews. As the reviews article notes, they are often the first notification of a problem the pharmacy should already have known about.
Can you bring dispensing back in-house?
In principle, yes. In practice, with considerable difficulty — and the asymmetry deserves stating before rather than after.
Capability atrophies quickly once volume leaves. Premises are surrendered or repurposed. Automation is not bought, then becomes a capital decision at the least convenient moment. Experienced dispensing staff move to employers who dispense. And the operational knowledge of running a dispensary at volume — real expertise, not a procedure — leaves with them.
The result: a decision presented as an operational choice is often, in practice, a one-way door. That is not a reason to refuse it. It is a reason to make it deliberately — reversal cost estimated honestly at the point of signature, and a retained capability if the business judges the dependency intolerable. An operator who cannot describe how they would bring dispensing back within six months has not made a reversible decision, whatever the contract says about notice.
What does it do to your valuation?
Both directions. The net effect depends on what a purchaser is buying.
It helps where a purchaser values asset-light scalability, predictable unit costs and no capital tied up in premises and automation — and where the arrangement demonstrably works, with clean governance.
It harms where diligence finds supplier concentration without redundancy, a contract terminable on short notice, no evidence of hub oversight, or margin that depends on terms the purchaser cannot be confident of keeping. A single-supplier dependency for the core operational function is precisely what diligence is designed to surface — and it is priced.
The practical instruction follows. If the business may be sold, document, govern and evidence the arrangement as though a purchaser's adviser were already reading it. Eventually one will.
When is hub and spoke the right answer?
Stated as this site's opinion, four conditions should hold together rather than individually.
Volume above the threshold, calculated on the business's own numbers rather than the hub's illustration, with the governance overhead included as a cost.
Differentiation that survives: the business competes on clinical service, outcomes or trust rather than the speed of a parcel, so outsourcing assembly does not outsource the proposition.
Governance capacity to oversee a supplier. The arrangement increases the governance burden, and the thematic review found that oversight is where operators most commonly fall short.
An honest continuity position: retained capability, a second option or contractual protection genuinely adequate to the risk.
Where all four hold, hub and spoke is a sound decision that frees a business to invest in what actually distinguishes it. Where the attraction is mainly that the numbers look difficult and the hub promises to make them easier, the honest reading is different. The business has a cost problem, and outsourcing will convert it into a dependency problem. Dependency problems are considerably harder to reverse.
What should be decided before signing?
Six decisions, each recorded. The hub's own materials will make none of them for the pharmacy.
The threshold volume at which this pays on our numbers, with governance costed in. What we still compete on once assembly leaves. Who owns this hub, what else they operate, and what protects our commercial information. What happens on the day the hub stops, expressed as a plan rather than a clause. What reversal would cost and how long it would take. And who inside this business owns the oversight, by name, with the authority and time to perform it.
Key takeaways
- Online pharmacies are the natural candidates: concentrated volume, standardised ranges, no counter and existing distance from the patient. That is why the decision arrives early and is often made on atmosphere.
- Savings are real in labour, premises and avoided capital. They are offset by higher governance overhead, transferred margin, and transition and coordination costs — producing a threshold below which the arrangement complicates without saving.
- The commoditisation risk is the strategic one. A business that has outsourced payments, delivery, prescribing, platform and now dispensing competes with identical rivals on price alone.
- Concentration risk is higher without a physical fallback: an online pharmacy losing hub access stops rather than degrades. That makes service levels, continuity terms, retained capability and notice periods strategic, not administrative.
- A hub necessarily observes volumes, mix, growth and seasonality, so establish who owns it and negotiate confidentiality extending to derived data.
- Patients and the regulator attribute everything to the supplying pharmacy, so invest in visibility, authority to resolve and treating hub performance as pharmacy performance.
- Reversal is far harder than starting, because capability atrophies. An operator who cannot describe bringing dispensing back within six months has made a one-way decision, whatever the notice period says.
Sources and further reading
FAQs
Oversight you can actually evidence.
Outsourcing assembly increases the governance burden rather than reducing it, and the oversight has to be evidenced. Dataforge PMR keeps the patient journey whole across a hub arrangement. The pharmacy that remains accountable can see status, resolve queries without chasing a supplier, and measure hub performance as its own.
See Dataforge PMR